Intracerebral Hemorrhage in Multiple Sclerosis: A Retrospective Cohort Study.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 15 06 2018
revised: 21 09 2018
accepted: 27 09 2018
pubmed: 6 11 2018
medline: 29 1 2019
entrez: 3 11 2018
Statut: ppublish

Résumé

To identify the vascular risk factors associated with the occurrence of intracerebral hemorrhage (ICH) in Multiple Sclerosis (MS) patients. This is an observational, retrospective cohort study using the nationwide electronic medical records (EMR) database. Patients with the diagnosis of MS were extracted from inpatient and outpatient EMR using the international classification of diseases, ninth/tenth revisions, clinical modification codes. We excluded patients younger than 18 years, and those where gender was not specified. Patients were further stratified based on their demographics, risk factors, medications, and comorbidities. Tobacco, diabetes, hypertension, and alcohol were the predicting variables; antiplatelet medication, and anticoagulant agents were the primary exposures for the development of ICH. A validated diagnosis code algorithm defined the diagnosis of ICH. Multivariable logistic regression models were utilized to assess the risk of ICH in MS patients. Of the total 57,099 MS patients (women: 75%, n = 41,517), 107 (.19%) sustained an ICH. Age (OR = 2.74, CI = 1.13-6.62), use of anticoagulants (OR = 2.15, 95% CI = 1.30-3.56, P = .0028), and history of tobacco exposure (OR = 2.44, CI = 1.37-4.36, P = .0025) were associated with increased risk of ICH. Use of antiplatelet and disease-modifying drugs (DMDs) showed a protective trend against ICH. Tobacco exposure and anticoagulant use were strongly associated with increased risk of ICH in patients with MS. There might be a protective effect that antiplatelet and DMDs have in the pathophysiology of this disease. Further prospective investigations are warranted to establish these associations.

Sections du résumé

BACKGROUND BACKGROUND
To identify the vascular risk factors associated with the occurrence of intracerebral hemorrhage (ICH) in Multiple Sclerosis (MS) patients.
METHODS METHODS
This is an observational, retrospective cohort study using the nationwide electronic medical records (EMR) database. Patients with the diagnosis of MS were extracted from inpatient and outpatient EMR using the international classification of diseases, ninth/tenth revisions, clinical modification codes. We excluded patients younger than 18 years, and those where gender was not specified. Patients were further stratified based on their demographics, risk factors, medications, and comorbidities. Tobacco, diabetes, hypertension, and alcohol were the predicting variables; antiplatelet medication, and anticoagulant agents were the primary exposures for the development of ICH. A validated diagnosis code algorithm defined the diagnosis of ICH. Multivariable logistic regression models were utilized to assess the risk of ICH in MS patients.
RESULTS RESULTS
Of the total 57,099 MS patients (women: 75%, n = 41,517), 107 (.19%) sustained an ICH. Age (OR = 2.74, CI = 1.13-6.62), use of anticoagulants (OR = 2.15, 95% CI = 1.30-3.56, P = .0028), and history of tobacco exposure (OR = 2.44, CI = 1.37-4.36, P = .0025) were associated with increased risk of ICH. Use of antiplatelet and disease-modifying drugs (DMDs) showed a protective trend against ICH.
CONCLUSIONS CONCLUSIONS
Tobacco exposure and anticoagulant use were strongly associated with increased risk of ICH in patients with MS. There might be a protective effect that antiplatelet and DMDs have in the pathophysiology of this disease. Further prospective investigations are warranted to establish these associations.

Identifiants

pubmed: 30385221
pii: S1052-3057(18)30572-X
doi: 10.1016/j.jstrokecerebrovasdis.2018.09.050
pii:
doi:

Substances chimiques

Anticoagulants 0
Antirheumatic Agents 0
Platelet Aggregation Inhibitors 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

267-275

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2018. Published by Elsevier Inc.

Auteurs

Maryam Zulfiqar (M)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Fares Qeadan (F)

Clinical and Translational Science Center, University of New Mexico, Albuquerque, New Mexico.

Asad Ikram (A)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Mudassir Farooqui (M)

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

Sarah P Richardson (SP)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Christopher S Calder (CS)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Syed A Quadri (SA)

Department of Neurosurgery, California Institute of Neurosciences, Thousand Oaks, California.

Puja Mathur (P)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Corey Ford (C)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Santiago O Gutierrez (S)

Department of Neurology, University of Iowa Hospitals and Clinic, Iowa City, Iowa.

Enrique Liera (E)

Department of Neurology, University of Iowa Hospitals and Clinic, Iowa City, Iowa.

Harry Snow (H)

Clinical and Translational Science Center, University of New Mexico, Albuquerque, New Mexico.

Joel N Gonzalez (J)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico.

Atif Zafar (A)

Department of Neurology, University of New Mexico, Albuquerque, New Mexico. Electronic address: azafar@salud.unm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH